Latest Healthcare News

Trajan Holdings delivered solid FY2025 results with revenue up 7.4% to $166.5 million and improved profitability despite transient costs and a biotech syringe loss. The company refinanced debt and set an optimistic FY2026 guidance range.

Trajan Group Holdings has reported record FY25 revenue of $166.5 million, beating guidance and setting a solid foundation for FY26 with continued organic growth and improved profitability.

Trajan Group Holdings Limited reported a 7.4% increase in revenue to $166.5 million for FY25, marking a significant turnaround with a return to profit after tax attributable to owners of $2.2 million. The company also reduced net debt and improved EBITDA by 26.2%, driven by organic growth and strategic acquisitions.

Alcidion Group Limited has delivered a record FY25 with $40.8 million in revenue and underlying EBITDA of $5.1 million, driven by a landmark $39 million UK electronic patient record contract and strong recurring revenue growth.

Alcidion Group Limited has reported a transformative FY25 with record earnings, a major NHS contract win, and a robust outlook for FY26. The company’s healthcare technology platform is gaining traction across the UK and Australia, setting the stage for accelerated growth.

NextEd Group reported a 13.9% revenue decline in FY25, yet maintained resilient EBITDA and strengthened its cash position, signaling a strategic reset underway to capture future growth.

NextEd Group Limited reported a 13.9% revenue decline to $95.9 million for FY25 but achieved a 53% improvement in net loss after tax, driven by cost savings and operational efficiencies. The company’s strategic repositioning includes leadership changes and expanded vocational offerings.

Australian Unity Limited reported robust FY2025 financial results, driven by strategic acquisitions and ongoing transformation efforts, returning to profitability with a $26.6 million net profit. The company is poised to complete its multi-year transformation by year-end and focus on growth amid rising demand for aged care and health services.

Australian Unity Limited reports a strong FY2025 financial turnaround with $136.2 million Adjusted EBITDA, driven by a multi-year transformation program focused on portfolio reshaping and technology integration.

Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.

Imagion Biosystems reported a $1.66 million loss for the half-year ending June 2025 while progressing its MagSense® HER2 Imaging Agent towards a Phase 2 FDA trial and securing $3.5 million in new funding.

Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.